Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement

This is a clinical practice guideline for women 35 or older who have not had a previous diagnosis of breast cancer. The guideline provides recommendations on the use of medication for breast-cancer risk reduction, specifically the selective estrogen receptor modulators tamoxifen and raloxifene, in women with a high or low risk of breast cancer. Outcomes of interest include breast cancer incidence (invasive, non-invasive, estrogen receptor positive, and estrogen receptor negative) and adverse effects of medication.